Conversely, the activated B-cell subtype was associated with higher concomitant expression of MYC and BCL-2 proteins (ie, double-expressor lymphomas) than the germinal centre B-cell subtype was by immunohistochemistry analysis (excluding double-hit lymphomas; 56 [54·9%] vs 45 [26%]; p<0·0001) and mRNA (109 [44·7%] vs 87 [18·3%]; p<0·0001; appendix p 13). Here, BCL2 is linked to lymphoma.